|
| 37589388 | A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered. | Neuro Oncol | 2024 |
| 37589388 | A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered. | Neuro Oncol | 2024 |
| 36335802 | The children's brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science. | Neoplasia | 2023 |
| 36335802 | The children's brain tumor network (CBTN) - Accelerating research in pediatric central nervous system tumors through collaboration and open science. | Neoplasia | 2023 |
| 36410226 | Interdisciplinary care of children with diffuse midline glioma. | Neoplasia | 2023 |
| 37584601 | Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. | Cancer Discov | 2023 |
| 37802053 | TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. | Cancer Cell | 2023 |
| 37609311 | Noninvasive molecular subtyping of pediatric low-grade glioma with self-supervised transfer learning. | medRxiv | 2023 |
| 37160547 | Cellular Therapy for Children with Central Nervous System Tumors: Mining and Mapping the Correlative Data. | Curr Oncol Rep | 2023 |
| 37091147 | Evaluating preclinical evidence for clinical translation in childhood brain tumours: Guidelines from the CONNECT, PNOC, and ITCC brain networks. | Front Oncol | 2023 |
| 36649671 | Retrospective dataset and survey analyses identify gaps in data collection for craniopharyngioma and priorities of patients and families affected by the disease. | Neoplasia | 2023 |
| 37145169 | ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma. | Cancer Res | 2023 |
| 36709715 | Past, present and future of Focused Ultrasound as an adjunct or complement to DIPG/DMG therapy: A consensus of the 2021 FUSF DIPG meeting. | Neoplasia | 2023 |
| 36642062 | Advances and Clinical Trials Update in the Treatment of Diffuse Intrinsic Pontine Gliomas. | Pediatr Neurosurg | 2023 |
| 36566593 | Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era. | Neoplasia | 2023 |
| 36698391 | Response and resistance to BRAF<sup>V600E</sup> inhibition in gliomas: Roadblocks ahead? | Front Oncol | 2023 |
| 37318058 | PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma. | Neuro Oncol | 2023 |
| 37195023 | ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma. | Cancer Res | 2023 |
| 36944450 | Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch <i>et al</i>. | J Immunother Cancer | 2023 |
| 36548930 | Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study. | J Clin Oncol | 2023 |
| 37379234 | Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. | Neuro Oncol | 2023 |
| 37244226 | Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology. | Neoplasia | 2023 |
| 36455411 | Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience. | Eur J Cancer | 2023 |
| 37492101 | OpenPBTA: The Open Pediatric Brain Tumor Atlas. | Cell Genom | 2023 |
| 37802053 | TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory. | Cancer Cell | 2023 |
| 37584601 | Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. | Cancer Discov | 2023 |
| 37609311 | Noninvasive molecular subtyping of pediatric low-grade glioma with self-supervised transfer learning. | medRxiv | 2023 |
| 37492101 | OpenPBTA: The Open Pediatric Brain Tumor Atlas. | Cell Genom | 2023 |
| 37160547 | Cellular Therapy for Children with Central Nervous System Tumors: Mining and Mapping the Correlative Data. | Curr Oncol Rep | 2023 |
| 37318058 | PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma. | Neuro Oncol | 2023 |
| 36944450 | Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch <i>et al</i>. | J Immunother Cancer | 2023 |
| 37379234 | Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. | Neuro Oncol | 2023 |
| 37244226 | Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology. | Neoplasia | 2023 |
| 37145169 | ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma. | Cancer Res | 2023 |
| 37195023 | ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma. | Cancer Res | 2023 |
| 37091147 | Evaluating preclinical evidence for clinical translation in childhood brain tumours: Guidelines from the CONNECT, PNOC, and ITCC brain networks. | Front Oncol | 2023 |
| 36548930 | Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study. | J Clin Oncol | 2023 |
| 36649671 | Retrospective dataset and survey analyses identify gaps in data collection for craniopharyngioma and priorities of patients and families affected by the disease. | Neoplasia | 2023 |
| 36642062 | Advances and Clinical Trials Update in the Treatment of Diffuse Intrinsic Pontine Gliomas. | Pediatr Neurosurg | 2023 |
| 36709715 | Past, present and future of Focused Ultrasound as an adjunct or complement to DIPG/DMG therapy: A consensus of the 2021 FUSF DIPG meeting. | Neoplasia | 2023 |
| 36566593 | Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era. | Neoplasia | 2023 |
| 36455411 | Real-time drug testing of paediatric diffuse midline glioma to support clinical decision making: The Zurich DIPG/DMG centre experience. | Eur J Cancer | 2023 |
| 36698391 | Response and resistance to BRAF<sup>V600E</sup> inhibition in gliomas: Roadblocks ahead? | Front Oncol | 2023 |
| 36410226 | Interdisciplinary care of children with diffuse midline glioma. | Neoplasia | 2023 |
| 34551970 | Repurposing Vandetanib plus Everolimus for the Treatment of <i>ACVR1</i>-Mutant Diffuse Intrinsic Pontine Glioma. | Cancer Discov | 2022 |
| 36172034 | Functional network alterations in young brain tumor patients with radiotherapy-induced memory impairments and vascular injury. | Front Neurol | 2022 |
| 35703183 | Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. | J Clin Invest | 2022 |
| 35945463 | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Acta Neuropathol | 2022 |
| 35814456 | An Integrated Analysis of Clinical, Genomic, and Imaging Features Reveals Predictors of Neurocognitive Outcomes in a Longitudinal Cohort of Pediatric Cancer Survivors, Enriched with CNS Tumors (Rad ART Pro). | Front Oncol | 2022 |
| 36068285 | Circulating tumor DNA sequencing provides comprehensive mutation profiling for pediatric central nervous system tumors. | NPJ Precis Oncol | 2022 |